SEATTLE — At the American Society of Retina Specialists annual meeting, the ReST Committee shared an update on intraocular inflammation reported in patients who received Syfovre.
Andre J. Witkin, MD, FASRS, chair-elect of the ASRS Research and Safety in Therapeutics (ReST) Committee, shared a timeline of events related to the cases of inflammation and Syfovre (pegcetacoplan injection, Apellis Pharmaceuticals). He said that the first report of panuveitis with retinal occlusive vasculitis was received by ReST’s reporting system on July 3. ReST contacted Apellis to discuss safety